Our Survivorship Studies

Browse our comprehensive listing of clinical studies available to cancer survivors.

and/or
22 Clinical Trials found
Cancer and its treatment may affect sexual and reproductive health. The purpose of this study is to evaluate sexual and reproductive health over several years among women age 50 and younger newly diagnosed with breast cancer or lymphoma.
Researchers want to find the best dose of ETX-19477 to treat cancer. The people in this study have solid tumors that keep growing even after treatment.
Researchers want to find the best dose of LY4066434 when given alone and with other drugs to treat solid tumors. The people in this study have cancer that has spread (advanced) or cannot be removed with surgery (inoperable). These include colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, and other solid tumors.
PF-07799544 and PF-07799933 both work by blocking proteins that promote melanoma growth. PF-07799544 blocks a family of proteins called MEK and PF-07799933 inhibits the BRAF protein. Both drugs are taken orally (by mouth).
Researchers want to find the best doses of different drugs to use together in people with advanced urothelial cancer. The people in this study have urothelial cancer that metastasized (spread) and has not yet been treated.
Researchers are assessing the effectiveness of the combination of lenvatinib, pembrolizumab immunotherapy, and fulvestrant to treat advanced breast cancer. The people in this study have inoperable or metastatic breast cancer (cancer that has spread) that is estrogen receptor-positive and HER2-negative.
Researchers want to learn if canakinumab can prevent cancer from developing in people with clonal cytopenia of undetermined significance (CCUS). In CCUS, there is a mutation (change) in one or more of the genes that help blood cells develop. People with CCUS have low levels of certain kinds of blood cells.
Roginolisib works by blocking a protein called PI3K-delta. By blocking this protein, roginolisib may strengthen your immune system's ability to fight cancer cells. It is taken orally (by mouth).
The purpose of this study is to see how well sotorasib works in people with advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) with a mutation (change) in the KRAS G12C gene. This mutation can cause cancer cells to grow. In addition, the people in this study have not received treatment for their cancer since it became advanced.
The combination of radiation therapy and chemotherapy (chemoradiation) is a standard treatment for people with HPV-positive throat cancer. HPV is human papillomavirus and can cause throat cancer. Radiation therapy uses radiation to kill cancer cells and shrink tumors. Chemotherapy stops the growth of cancer cells, either by killing the cells or stopping them from dividing. However, this standard combination may cause severe side effects because it is given over 7 weeks. These side effects include sores in the mouth and gut, sore throat, and changes in taste.